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Abstract
Background: Recent studies have identi ed susceptibility genes of HBV clearance, chronic hepatitis B, liver cirrhosis,
hepatocellular carcinoma, and showed the host genetic factors play an important role in these HBV-related outcomes.
Results: In order to discover new susceptibility genes for HBV-related outcomes, we conducted a genome-wide association study
in 1031 Chinese participants, including 275 HBV clearance subjects, 92 asymptomatic persistence infection carriers (ASPI), 93
chronic hepatitis B patients (CHB), 188 HBV-related decompensated cirrhosis patients (DC), 214 HBV-related hepatocellular
carcinoma patients (HCC) and 169 healthy controls (HC). In the case-control study, we observed novel locus signi cantly
associated with CHB (SNP: rs1264473, Gene: GRHL2, P = 1.57×10-6) and HCC (SNP: rs2833856, Gene: EVA1C, P = 1.62×10-6;
SNP: rs4661093, Gene: ETV3, P = 2.26×10-6). In the trend study across progressive stages post HBV infection, one novel locus
(SNP: rs1537862, Gene: LACE1, P = 1.85×10-6), and three MHC loci (HLA-DRB1, HLA-DPB1, HLA-DPA2) showed
signi cant increased progressive risk from ASPI to CHB. Interestingly, underlying the evolutionary study of HBV-related genes in
public database, we found that the derived allele of two HBV clearance related locus, rs3077 and rs9277542, are under strong
selection in European population.
Conclusions: In this study, we identi ed several novel candidate genes associated with individual HBV infectious outcomes,
progressive stages, and liver enzymes. Moreover, we identi ed two SNPs that show selective signi cance (HLA-DPA1, HLA-
DPB1) in non-East Asian (European, American, South Asian) versus East Asian, indicating that host genetic factors contribute to
the ethnic disparities of susceptibility of HBV infection. Taken together, these  ndings provided a new insight into the role of
host genetic factors in HBV related outcomes and progression. 
Background
Hepatitis B virus (HBV) infection is one of the most common infectious diseases, with about 248 million HBsAg positive
individuals worldwide and the largest HBsAg positive population in China [1]. HBV infection can develop a wide spectrum of liver
diseases, including chronic hepatitis B, liver cirrhosis, hepatocellular carcinoma [2–4]. Previous studies showed the host genetic
factor played a critical role in HBV infection susceptibility and identi ed associated SNPs with signi cant contribution, including
major histocompatibility complex (MHC) genes, i.e. HLA-DPA1 (rs3077), HLA-DPB1 (rs9277535), HLA-C (rs3130542), HLA-DQ
(rs2856718, rs7453920) [5–7], and non-MHC genes, i.e. UBE2L3 (rs4821116), INTS10 (rs7000921) [8, 9]. In advanced stages of
HBV disease, host genetic factors in uence the outcome of HBV infection [7, 10, 11], including HLA-DQ (rs9275319), HLA-DRB1
(rs2647073, rs3997872), STAT4 (rs7574865), C2 (rs9267673), PNPLA3 (rs738408, rs738409), SLC17A2 (rs80215559), HFE
(rs1800562) [12, 13] for liver cirrhosis and KIF1B (rs17401966), HLA-DQA1/DRB1 (rs9272105), HLA-DQ (rs9275319), STAT4
(rs7574865) for hepatocellular carcinoma [14–16]. However, these reported HBV-related genes confer relatively small increments
in risk and explain a small proportion of heritability. For example, although MHC genes are important for immune response to
HBsAg, more than half the heritability is determined by non-MHC genes [17]. Moreover, previous studies showed that the MHC
genes share a common in uence on HBV infection, liver cirrhosis, hepatocellular carcinoma [6, 12, 15, 16] as well as associating
with different risk in these outcomes [18]; i.e. HLA-DQ, STAT4, C2, HLA-DRB1 for liver cirrhosis and HCC [12], HLA-DQ for CHB [6].
These consistent [12] or different [18] risks indicated shared but also modi ed effects for progressive HBV-related outcomes.
These results raised our interest to identify host genetic factor which increases the risk of progressive stages post HBV infection.
To reveal new susceptibility genes for HBV infection and the HBV-related outcomes, we performed a genome-wide association
study (GWAS) in 1031 participants, including 275 HBV clearance subjects, 92 asymptomatic persistence infection carriers
(ASPI), 93 chronic hepatitis B patients (CHB), 188 HBV-related decompensated cirrhosis patients (DC), 214 HBV-related
hepatocellular carcinoma patients (HCC) and 169 healthy controls (HC) (Table 1).
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Table 1
Characteristics of participants in the genome-wide association cohorts
Disease categories HBV
clearance
ASPI CHB DC HCC HC
Sample size 275 92 93 188 214 169
Mean age ± SD 49.56 ± 8.8 46.89 ± 6.9 46.46 ± 5.7 50.65 ± 8.4 51.34 ± 10.5 48.82 ± 7.1
Male/female 105/170 33/59 62/31 148/40 183/31 73/96
















13.68 ± 9.93 12.28 ± 2.91 23.12 ± 35.60 65.87 ± 83.22 50.11 ± 90.93 12.95 ± 4.09
DBiL, µmol/L, mean 
± SD
5.86 ± 18.39 3.59 ± 1.68 9.36 ± 14.29 35.15 ± 51.33 25.87 ± 55.04 4.54 ± 9.46




















ALB, g/L, mean ± SD 43.33 ± 6.11 44.16 ± 6.71 42.40 ± 42.25 32.28 ± 7.13 37.19 ± 7.27 43.93 ± 4.96























Abbreviations: ASPI, asymptomatic persistence infection; CHB, chronic hepatitis B; DC, decompensated cirrhosis; HCC,
hepatocellular carcinoma; HC, healthy controls; SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; ALP, alkaline phosphatase; GGT, glutamyl transpeptidase.
Methods
Study Participants
A total of 1104 unrelated, age- and gender- matched, Chinese participants were recruited in the study, enrollment criteria were
consistent with a previous report [19]. The population of HBV-related phenotypes was composed of  ve subgroups: HBV
clearance subjects, asymptomatic persistence infection (ASPI) carriers, chronic hepatitis B (CHB) patients, HBV-related
decompensated cirrhosis (DC) patients, HBV-related hepatocellular carcinoma (HCC) patients. Healthy controls (HC) who were
HBV serum marker-negative (HBsAg, anti-HBc) and had no serological evidence of co-infection with HCV, HDV, and HIV were also
included. HBV chronic infection patients were diagnosed based on seropositivity of HBsAg at least 6 months. Then ASPI was
de ned as HBsAg and anti-HBc positive at least 6 months and serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST) in normal values without abnormal before. CHB is de ned as HBsAg and anti-HBc positive at least 6
months and ALT, AST abnormal before or at enrollment. DC was de ned as HBsAg and anti-HBc positive at least 6 months with
decompensated portal hypertension (gastroesophageal bleeding, ascites, edema or encephalopathy) or decompensated liver
function (albumin < 35 g/L and total bilirubin > 35umol/L). HCC was de ned at least one of following: (a) liver biopsy; or (b)
abnormal alpha fetoprotein (AFP) and sonographic, CT or MRI space occupying evidence.
Clinical Parameters
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Clinical parameters including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL),
direct bilirubin (DBIL), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT), albumin (ALB), globulin (Glo), alpha
fetoprotein (AFP), prothrombin time activity (PTA), platelets (PLT), HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc were collected
from hospital information system. Other baseline characteristics were recorded during each patient’s clinical examination. In
brief, liver biochemistry and virological tests were carried out by Bechman Coulter AU chemistry analyzers, chemiluminescence
immunoassays (AxSYM or ARCHITECT I2000, Abbott, USA) or Ortho/Chemi-luminescent assay (Johnson and Johnson Co.,
USA) with commercially available kits; Anti-HAV IgM antibody, HDV antigen (HDAg) and anti-HDV antibody, and anti-HEV
antibody were determined by commercially ELISA kits in China. For HBV DNA level, it was quanti ed using commercial real-time
polymerase chain reaction kit with a lower limit of detection (LLOD) of 100 IU/ml (Daan company, China) or Roche Cobas
Ampliprep/Cobas Taqman™ PCR assay with LLOD of 20 IU/ml (Roche, USA).
Genome-wide SNP Genotyping and Quality Control
Genotyping was performed on Affymetrix 500 k Genome-Wide Human SNP Array 6.0
(http://www.affymetrix.com/Auth/analysis/downloads/na35/genotyping/GenomeWideSNP_6.na35.annot.csv.zip). SNPs met
the following quality control procedures were excluded: 1) call rate < 95%; 2) minor allele frequency (MAF) < 1%; 3) genotype in
controls deviated from the Hardy Weinberg equilibrium (HWE test P-value < 10− 5). Overall, 1,031 samples and 607,153 variants
on 22 chromosomes were included in the  nal analysis.
Statistics Analysis
GCTA tool [20] was used to perform principal component analyses for estimating population substructure. The  rst two
eigenvectors, pc1 and pc2, were used to display the population structure. PLINK 1.9 [21] software was used to perform logistic
regression for identifying susceptibility SNPs of HBV infection and HBV-related outcomes. Gender and age were used as
covariates in logistic regression. Chi-square test for trend in proportions was used to identify SNPs with increased effectiveness
on disease progression. We used the Bonferroni method to adjust the false positive rate caused by multiple test. The number of
independent LD block was used to represent the number of independent multiple test. We calculated a total of 21,077
independent LD blocks via GEC [22] and then set 0.05/21077 as the threshold of genome-wide signi cance. The genomic
control method was used to measure population strati cation by calculating the genomic in ation factor (λ) from median P-
value. ANOVA was used to evaluate the signi cance of the association between biomarkers and genotypes in healthy controls.
Using the SNPs in HBV infection-related loci in 1000 Genomes Project [23], we performed evolutional analyses, including
building phylogenetic tree, detecting the signatures of selection, displaying the core haplotypes, estimating effective population
size. Derived allele and ancestral allele of SNPs were accessed from Ensemble human ancestral genome
(http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/supporting/ancestral_alignments). PoMo [24], an allele
frequency-based approach, was used to build the racial tree based on the allele frequency of SNPs in each population. FST [25], a
classical metrics of population differentiation, was widely employed in detecting signatures of selection [26] in human genome
[27, 28] and animal genome [29–31]. In our study, FST was implemented to detect the selective signature between East Asian
population and each other population. Vcftools [32] was used to calculate the FST statistics of SNPs in paired populations. FST
statistics accesses 0.15 [33] was used as a threshold to detect the signature of selection. Rehh package [34, 35] was used to
display the haplotype bifurcation diagrams of the associated SNPs in different populations. Relate [36], a method for genome-
wide genealogy estimation for thousands of samples, was used to estimate the historical population size at default setting.
Results
The demographic and clinical characteristics of 1031 study participants included in our association study are presented in
Table 1. All participants were genotyped by Affymetrix 500 k SNP Array. A total of 607,153 SNPs passed through quality control
(Supplementary Figure S1). These SNPs  ltered minor allele frequency of < 1% and a call rate of < 95%.
To demonstrate that there is no genetic strati cation in the population, we performed a principal component analysis on the
SNPs of all participants. The  rst two principal components show absence of population structure (Supplementary Figure S2).
To identify susceptibility SNPs for HBV infection, we performed a GWAS in HBV infection similar with previous design [8, 9]. HBV
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clearance was used as a control group versus ASPI, CHB, DC, HCC as HBV chronic infection (case group). We observed
associations of two novel MHC loci with progression to certain HBV stages (SNP: rs2395166, Gene: HLA-DRA, P = 1.42 × 10− 7;
SNP: rs615672, Gene: HLA-DRB1, P = 8.54 × 10− 7) and two reported MHC locus (SNP: rs3077, Gene: HLA-DPA1, P = 6.60 × 10− 9;
SNP: rs9277542, Gene: HLA-DPB1, P = 1.53 × 10− 8) (Table 2; Fig. 1). These MHC loci variants replicated association results of
previous studies a rming that MHC gene alleles confer risks of susceptibility of HBV infection in East Asian. Interestingly, we
founded that these reported MHC loci (rs2395166:C, rs615672:G, rs3077:A, rs9277542:T, rs9277341:T) present signi cant
differences in allele frequency between East Asian and non-East Asian population in gnomAD database (Table 3), as well as the
differences between HBV infection group and HBV clearance group. Since different groups may not present an identical minor
allele, here, we used the derived allele against the ancestral allele for studying the allele frequency across different populations.
The derived allele frequencies in East Asian are much closer to the HBV chronic infection group, while other populations, such as
European, are much closer to the HBV clearance group. These genetic differences may suggest a selective signal in non-East
Asian population versus East Asian population. To con rm this, we  rstly build a phylogenetic tree based on these loci and then
showed the genetic diversity in world-wide populations, in which the East Asian population is at the root. We set the East Asian
as the ancestral group in these loci according to the derived allele frequencies and the phylogenetic tree. Subsequently, we
identi ed two strong phylogenetic signals (HLA-DPA1, HLA-DPB1) in the European population (Fig. 2) via FST method. Haplotype
bifurcation diagrams of the two core SNPs (rs3077, rs9277542) presented that the resisted allele lead to a long-range, and a
high frequency homozygosity in European population (Fig. 3), con rming the natural genetic selection. These evidences
revealed that the resisted alleles were under positive selection in European population strongly. We estimated the historic
population size and then showed these two loci (HLA-DPA1, HLA-DPB1) were under selection during the past 26,000 years
(Supplementary Figure S3). These results may provide a context for the racking in uence of HBV infectious diseases in history.
Table 2
The signi cance of HBV-related outcomes study
































0.5353 T 0.3735 0.5347 (Kamatani
et al., 2009)
CHB (93) ASPI (92) rs1264473 GRHL2 1.57 × 
10− 6
3.931 C 0.4402 0.1957 Novel 1.052
HCC
(214)
CHB (93) rs2833856 EVA1C 1.62 × 
10− 6
0.3515 C 0.2243 0.4086 Novel 1.022
HCC
(214)
DC (188) rs4661093 ETV3 2.26 × 
10− 6
2.841 A 0.2104 0.0882 Novel 1.022
Abbreviations: OR, odds ratio; ASPI, asymptomatic persistence infection; CHB, chronic hepatitis B; DC, decompensated
cirrhosis; HCC, hepatocellular carcinoma; MHC, major histocompatibility complex; λ: statistic of genomic control.
 
Table 3: Divided allele frequency of signi cant SNPs in MHC region
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SNP Study Population Derived
Allele
Derived Allele Frequency   P value
Case-control studies gnomAD   East Asian
vs non-East






rs2395166 our study Chinese C 0.127 0.218 0.183 0.128 0.367   4.367×10-195
rs615672 our study Chinese G 0.405 0.528 0.512 0.388 0.590   6.003×10-111




















0.206 0.276 0.288  




Chinese 0.133 0.237 0.237  




Japanese 0.246 - 0.437  
Abbreviations: East Asian, East Asian population in gnomAD database; non-East Asian, combined all other population excepted
East Asian in gnomAD database; P value, compared allele frequency between East Asian and non-East Asian population via
 sher exact test. Derived Allele was accessed from human ancestral genome (Ensembl-59).
 
To identify new susceptibility locus for HBV-related outcomes, we performed association studies for CHB, DC, and HCC.
Signi cantly, we observed three associated gene SNP loci: 1) (SNP: rs1264473, Gene: GRHL2, P = 1.57 × 10− 6) associated with
CHB versus ASPI; 2) (SNP: rs2833856, Gene: EVA1C, P = 1.62 × 10− 6) associated with HCC versus CHB; and 3) (SNP: rs4661093,
Gene: ETV3, P = 2.26 × 10− 6) associated with HCC versus DC (Table 2; Fig. 1). No SNP associated with DC versus CHB were
apparent.
HBV clearance, ASPI, CHB, DC, and HCC are progressive stages post HBV infection [4]. We hypothesized that the host genetic
factor contributes to the development of outcomes, as well as to the individual outcome. To investigate this hypothesis, we test
two progressive stages upon HBV infection: 1.) HBV infection itself (CHB, ASPI, and HBV clearance) and 2.) development of CHB
(CHB, DC, and HCC). We performed a chi-square test for trend in proportions of allele to identify SNPs increasing risk of HBV-
related outcomes in the progressive stages. We observed association with one novel locus (SNP: rs1537862, Gene: LACE1, P = 
1.85 × 10− 6), one association with a reported locus (SNP: rs9277542, Gene: HLA-DPB1, P = 1.50 × 10− 9), and two association
variants at MHC genes (SNP: rs615672, Gene: HLA-DRB1, P = 1.39 × 10− 6; SNP: rs3128923, Gene: HLA-DPA2, P = 2.06 × 10− 6)
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with trend test of allele frequency across three outcomes (Table 4; Fig. 4A). The three reported MHC genes were demonstrated to
play a critical role in the resistance of HBV infection, and two (HLA-DPB:rs9277542, HLA-DRB1:rs9277542) were identi ed to be
associated with HBV clearance (Table 2). We did not observe any SNPs achieve genome-wide signi cant association with
development of CHB; Two additional loci (SNP: rs6942409, Gene: AC011288.2, P = 3.08 × 10− 6) and the HCC associated locus
(SNP: rs2833856, Gene: EVA1C, P = 1.62 × 10− 5) were associated with increased risk of DC and HCC during the development of
CHB (Table 5; Fig. 4B).
Table 4
The signi cance of progressive HBV infection study
SNP Gene P value Resistant
Allele
Resistant Allele Frequency   Related Risk


















G 0.3804 0.4348 0.5636   0.89 1.14
rs1537862 LACE1 1.85 × 
10− 6
C 0.6 0.6374 0.7647   0.92 1.19
Abbreviations: ASPI, asymptomatic persistence infection; CHB, chronic hepatitis B. RR was calculated with the comparison
of CHB and ASPI, Clearance and ASPI respectively.
Table 5
The suggestive signi cance of progressive CHB study
SNP Gene P value Risk Allele Risk Allele Frequency   Related Risk
CHB DC HCC   DC (vs CHB) HCC (vs CHB)
rs6942409 AC011288.2 3.08 × 10− 6 G 0.6129 0.7287 0.7958   1.20 1.37
rs2833856 EVA1C 1.62 × 10− 5 T 0.5914 0.75 0.7757   1.30 1.35
Abbreviations: CHB, chronic hepatitis B; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma. RR was calculated
with the comparison of HCC and CHB, DC and CHB respectively.
Host genetic factors were demonstrated to in uence concentrations of liver enzymes in plasma, which are widely used to
indicate liver disease [37, 38] Here, to investigate the functional change in liver in uenced by the HBV related loci described
above, we performed a variance analysis in 10 clinical parameters of serum liver enzymes (ALT, AST, TBIL, DBIL, ALP, GGT, ALB,
AFP, PTA, and PLT) between different genotypes in healthy controls (Supplementary Figure S4-9). Six loci (rs1537862,
rs3128923, rs9277542, rs9277341, rs9277378, rs4661093) showed modest associations with concentrations of liver enzymes,
including ALB, ALP, AFP, and PTA (Fig. 5). These associations suggest pathways linking the host genetic factors, metabolism,
and liver function for understanding the mechanisms of infection and disease progression.
In sum, our study identi ed susceptibility SNPs associated with HBV related outcomes and SNPs increased the risk of




HBV infection leads to a wide spectrum of clinical outcomes, including spontaneous clearance, asymptomatic carrier, chronic
hepatitis B, liver cirrhosis, and hepatocellular carcinoma. Previous studies showed that MHC genes played an important role in
outcomes of HBV infection [7]. Alleles associated with HBV infection versus HBV clearance affect infection risk, and a low-risk
allele indicated an effect on virus clearance. By contrast loci associated with CHB versus ASPI indicated risk for the severe
progression, while a low-risk allele affected tolerance of virus. The tolerance-related gene, GRHL2, was demonstrated to
in uence the in ammation in hepatocytes by regulating microRNA 122 (MIR122) and the target of MIR122, HIF1α [39]. Levels of
GRHL2 were increased in liver tissues of patients with alcoholic liver disease and correlated with decreases in levels of MIR122.
Increased levels of MIR122 in hepatocytes of mice with ethanol-induced liver disease and advanced  brosis reduced levels of
HIF1α and reduced serum levels of alanine aminotransferase (ALT). Taken together, we propose that the low-risk allele
rs1264473:T at GRHL2 ablates severe persistent in ammation through increased the levels of MIR122.
Our previous studies [40, 41] showed that NTCP S267F mutation signi cantly affected the disease progression to cirrhosis (P = 
0.017), and hepatocellular carcinoma (P = 0.023) versus CHB [40] and the rs3077:T allele was associated with decreased risk of
chronic HBV infection (OR = 0.62, P = 0.001) [41]. In this study, we searched for host genetic factor with increased risk of the
development-related outcomes in GWAS. One novel locus, LACE1, and three infection-related MHC loci were associated the
progression of HBV infection. These results showed that the host genetic factors, both MHC and non-MHC genes, increased the
risk of progressive outcomes post HBV infection, as well as HBV mutation. It is reported that HBV infection altered the
mitochondrial metabolism and mitochondrial dynamics, which result in mitochondrial injury and liver disease [42]. LACE1 was
reported to affect mitochondrial protein homeostasis [43]. Knockdown of LACE1 converted the expression of a crucial
component of regulating mitochondrial dynamics, OPA1 [43–45]. In addition, we found that the risk allele, LACE1:rs1537862:T,
decreased the level of ALB signi cantly (P = 0.025, Fig. 5). ALB is a critical marker decreasing with the deterioration of chronic
liver diseases [46–48]. Biosynthesis of ALB was affected by proin ammatory cytokines [49, 50] and excess amounts of
oxidative agents released by mitochondria from injured liver [46, 51]. Taken together, we proposed LACE1 may affect hepatic
infection by changing the hepatic mitochondrial metabolism and leading to the progression of HBV infection.
There is a limitation in our study, that is we do not have an additional cohort for replicate study. In spite of that, we showed the
reported loci in MHC region are signi cantly related to HBV infection. These replicate results of previous studies con rm our
 ndings are reliable and provide con dence for our study in this cohort. Here, we provide novel candidate genes related to
individual outcomes, progressive stages, and liver enzymes. Moreover, we identi ed two SNPs that show selective signi cance
(HLA-DPA1, HLA-DPB1) in non-East Asian (European, American, South Asian) versus East Asian. East Asian populations seem
more susceptible to HBV infection than non-EAS Asian, and the differences of susceptibility were affected by HBV genotype [52],
immunity [53], and environmental exposure [53, 54]. Even in an identical environment (United States), Asian are more prevalent
in chronic HBV infection than non-Asian [53]. It seems likely that host genetic factors contribute to the ethnic disparities of
susceptibility of HBV infection. Taken together with the genetic associations and evolutionary signals, our  ndings provide a
new insight for HBV study.
Conclusion
In case-control study, we identi ed one novel locus (SNP: rs1264473, Gene: GRHL2, P = 1.57 × 10− 6) signi cantly associated
with CHB, two novel locus (SNP: rs2833856, Gene: EVA1C, P = 1.62 × 10− 6; SNP: rs4661093, Gene: ETV3, P = 2.26 × 10− 6)
signi cantly associated with HCC. In trend study across multiple outcomes, we identi ed one novel locus (SNP: rs1537862,
Gene: LACE1, P = 1.85 × 10− 6) and three MHC loci (HLA-DRB1, HLA-DPB1, HLA-DPA2) signi cantly increased progressive risk
from CHB through ASPI to HBV clearance. In evolutionary study, we showed the derived allele of two HBV clearance related
locus, rs3077 and rs9277542, are under strong selection in European population. We suggested these selected alleles may play
a role in resisting the susceptibility of HBV in Europeans. Our  ndings provided a new insight into the role of host genetic factors









anti-HBc Antibody to Hepatitis B core Antigen
anti-HBe Antibody to Hepatitis B e Antigen
anti-HBs Antibody to Hepatitis B surface Antigen
anti-HDV Antibody to Hepatitis D Virus
anti-HEV Antibody to Hepatitis E Virus
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GWAS Genome Wide Association Study
HBeAg Hepatitis B e Antigen
HBsAg Hepatitis B surface Antigen
HBV Hepatitis B Virus
HCC Hepatocellular Carcinoma
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HCV Hepatitis C Virus
HDV Hepatitis D Virus
HIV Human Immunode ciency Virus
HWE Hardy-Weinberg Equilibrium
MAF Minor Allele Frequency
MHC Major Histocompatibility Complex
PI Persistence Infection
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SNP Single Nucleotide Polymorphism
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Figures
Figure 4
The raising allele frequency in HBV related outcomes during the progression. Four SNPs with increased resistance in CHB, ASPI,
HBV clearance during HBV infection (A) and two SNPs with increased risk in the CHB, DC, HCC during the development of CHB
(B). Abbreviation: ASPI, asymptomatic persistence infection; CHB, chronic hepatitis B; DC, decompensated cirrhosis; HCC,
hepatocellular carcinoma.
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